|
The Tufts Center for the Study of Drug Development has announced it has developed the first comprehensive estimate of the average cost of developing a new biotechnology product, ....
and pegged it at $1.2 billion.
Tufts CSDD said the $1.2 billion estimate reflects the costs of drugs that fail in testing and the time costs associated with bringing a new biopharmaceutical to market. Of this amount, capitalized out-of-pocket preclinical cost totaled $615 million, while similar clinical period cost totaled $626 million.
yeah... they just do it to be kind. certainly shouldn't have their investment and rights protected.
|